StockData
SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc. (SLS) income statement

SLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$17.95−1.20 (-6.27%)

Close on Nov 18, 2026Market cap $3.62BP/E –Yield –

SELLAS Life Sciences Group, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin
–
Operating margin
–
Net margin
–
Return on equity, FY2025
-66.9%

Financial strength

Current ratio
18.83
Debt to equity
–
Debt to assets
–
Cash to current liabilities
1827.8%

Valuation

P/E ratio
–
Price to sales
–
Price to book
26.33
Dividend yield
–

See a number that looks wrong?